Offenes Foramen ovale – wann verschließen?

Abstract

For more than two decades, the role of patent foramen ovale (PFO) as a source for cardioembolic ischemic stroke or transient ischemic attack (TIA) and its therapy are discussed controversially. Since the introduction of interventional transcatheter closure devices the number of such interventions is increasing. This article summarizes current research regarding the association of PFO and cerebrovascular ischemic events, presents current knowledge regarding medical and interventional treatment options and gives recommendations for treatment decision making in individual patients.

Literatur

• 1 Hagen P T, Scholz D G, Edwards W D. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts.  Mayo Clin Proc. 1984;  59 17-20
• 2 Meissner I, Khandheria B K, Heit J A et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study.  J Am Coll Cardiol. 2006;  47 440-445
• 3 Schneider B, Zienkiewicz T, Jansen V et al. Diagnosis of patent foramen ovale by transesophageal echocardiography and correlation with autopsy findings.  Am J Cardiol. 1996;  77 1202-1209
• 4 Hansen A, Kuecherer H. Caught in the act: entrapped embolus through a patent foramen ovale.  Eur J Echocardiogr. 2008;  9 692-693
• 5 Thanigaraj S, Zajarias A, Valika A et al. Caught in the act: serial, real time images of a thrombus traversing from the right to left atrium across a patent foramen ovale.  Eur J Echocardiogr. 2006;  7 179-181
• 6 Berthet K, Lavergne T, Cohen A et al. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause.  Stroke. 2000;  31 398-403
• 7 Overell J R, Bone I, Lees K R. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies.  Neurology. 2000;  55 1172-1179
• 8 Force M, Massabuau P, Larrue V. Prevalence of atrial septal abnormalities in older patients with cryptogenic ischemic stroke or transient ischemic attack.  Clin Neurol Neurosurg. 2008;  110 779-783
• 9 Handke M, Harloff A, Olschewski M et al. Patent foramen ovale and cryptogenic stroke in older patients.  N Engl J Med. 2007;  357 2262-2268
• 10 Mattle H P, Meier B, Nedeltchev K. Prevention of stroke in patients with patent foramen ovale.  Int J Stroke. 2010;  5 92-102
• 11 Di Tullio M R, Sacco R L, Sciacca R R et al. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population.  J Am Coll Cardiol. 2007;  49 797-802
• 12 Carpenter D A, Ford A L, Lee J M. Patent foramen ovale and stroke: Should PFOs be closed in otherwise cryptogenic stroke?.  Curr Atheroscler Rep. 2010;  12 251-258
• 13 Cramer S C, Rordorf G, Maki J H et al. Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study.  Stroke. 2004;  35 46-50
• 14 Bogousslavsky J, Garazi S, Jeanrenaud X et al. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group.  Neurology. 1996;  46 1301-1305
• 15 Lethen H, Flachskampf F A, Schneider R et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack.  Am J Cardiol. 1997;  80 1066-1069
• 16 Mas J L, Arquizan C, Lamy C et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.  N Engl J Med. 2001;  345 1740-1746
• 17 Homma S, Sacco R L, Di Tullio M R et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study.  Circulation. 2002;  105 2625-2631
• 18 Serena J, Marti-Fabregas J, Santamarina E et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study.  Stroke. 2008;  39 3131-3136
• 19 Messe S R, Silverman I E, Kizer J R et al. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2004;  62 1042-1050
• 20 Almekhlafi M A, Wilton S B, Rabi D M et al. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis.  Neurology. 2009;  73 89-97
• 21 Nedeltchev K, Arnold M, Wahl A et al. Outcome of patients with cryptogenic stroke and patent foramen ovale.  J Neurol Neurosurg Psychiatry. 2002;  72 347-350
• 22 Deutsche Gesellschaft für Neurologie .Primär- und Sekundärprävention der zerebralen Ischämie. Gemeinsame Leitlinie der DGN und der Deutschen Schlaganfallgesellschaft (DSG) 2008. http://www.dsg-info.de/images/stories/DSG/PDF/Leitlinien/ll08kap_024.pdf ; Stand: 4.10.2010
• 23 King T D, Thompson S L, Steiner C et al. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization.  JAMA. 1976;  235 2506-2509
• 24 Bridges N D, Hellenbrand W, Latson L et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism.  Circulation. 1992;  86 1902-1908
• 25 Taaffe M, Fischer E, Baranowski A et al. Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder).  Am J Cardiol. 2008;  101 1353-1358
• 26 Martin F, Sanchez P L, Doherty E et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism.  Circulation. 2002;  106 1121-1126
• 27 Wahl A, Meier B. Patent foramen ovale and ventricular septal defect closure.  Heart. 2009;  95 70-82
• 28 Krumsdorf U, Ostermayer S, Billinger K et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients.  J Am Coll Cardiol. 2004;  43 302-309
• 29 Kiblawi F M, Sommer R J, Levchuck S G. Transcatheter closure of patent foramen ovale in older adults.  Catheter Cardiovasc Interv. 2006;  68 136-142; discussion 143 – 144
• 30 Alaeddini J, Feghali G, Jenkins S et al. Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale.  J Invasive Cardiol. 2006;  18 365-368
• 31 Dowson A, Mullen M J, Peatfield R et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache.  Circulation. 2008;  117 1397-1404
• 32 Braun M, Gliech V, Boscheri A et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems.  Eur Heart J. 2004;  25 424-430
• 33 Windecker S, Wahl A, Nedeltchev K et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke.  J Am Coll Cardiol. 2004;  44 750-758
• 34 Schuchlenz H W, Weihs W, Berghold A et al. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale.  Int J Cardiol. 2005;  101 77-82
• 35 http://www.theheart.org/article/1088789.do Stand: 4. 10. 2010